Nenad Macesic1,2, Brian Nelson3, Thomas H Mcconville1, Marla J Giddins1,4, Daniel A Green5, Stephania Stump1,4, Angela Gomez-Simmonds1, Medini K Annavajhala1,4, Anne-Catrin Uhlemann1,4. 1. Division of Infectious Diseases, Columbia University Irving Medical Center, New York City, New York. 2. Central Clinical School, Monash University, Melbourne, Australia. 3. Department of Pharmacy, Columbia University Irving Medical Center/New York Presbyterian Hospital, New York City, New York. 4. Microbiome & Pathogen Genomics Core, , New York City, New York. 5. Clinical Microbiology Laboratory, Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York City, New York.
Abstract
BACKGROUND: Polymyxins are antimicrobials of last resort for the treatment of carbapenem-resistant Enterobacteriaceae, but resistance in 5% to >40% isolates has been reported. We conducted a genomic survey of clinical polymyxin-resistant (PR) Klebsiella pneumoniae to determine the molecular mechanisms of PR and the role of polymyxin exposure versus transmission in PR emergence. METHODS: We included 88 patients with PR K. pneumoniae from 2011-2018 and collected demographic, antimicrobial exposure, and infection data. Whole-genome sequencing was performed on 388 isolates, including 164 PR isolates. Variant calling and insertion sequence detection were performed, focusing on key genes associated with PR (mgrB, crrAB, phoPQ, and pmrAB). We conducted phylogenetic analyses of key K. pneumoniae multi-locus sequence types (ST258, ST17, ST307, and ST392). RESULTS: Polymyxin exposure was documented in 53/88 (60%) patients prior to PR detection. Through an analysis of key PR genes, we detected 129 individual variants and 72 unique variant combinations in PR isolates. This included multiple, distinct changes in 36% of patients with serial PR isolates. Insertion sequence disruption was limited to mgrB (P < .001). Polymyxin minimum inhibitory concentrations showed stepwise increases with the number of PR genes affected (P < .001). When clusters containing PR isolates in ≥2 patients were analyzed, 10/14 had multiple genetic events leading to PR. CONCLUSIONS: Molecular mechanisms leading to PR in clinical K. pneumoniae isolates are remarkably heterogenous, even within clusters or individual patients. Polymyxin exposure with de novo PR emergence led to PR in the majority of patients, rather than transmission. Optimizing polymyxin use should be a key strategy in stopping the spread of PR.
BACKGROUND: Polymyxins are antimicrobials of last resort for the treatment of carbapenem-resistant Enterobacteriaceae, but resistance in 5% to >40% isolates has been reported. We conducted a genomic survey of clinical polymyxin-resistant (PR) Klebsiella pneumoniae to determine the molecular mechanisms of PR and the role of polymyxin exposure versus transmission in PR emergence. METHODS: We included 88 patients with PR K. pneumoniae from 2011-2018 and collected demographic, antimicrobial exposure, and infection data. Whole-genome sequencing was performed on 388 isolates, including 164 PR isolates. Variant calling and insertion sequence detection were performed, focusing on key genes associated with PR (mgrB, crrAB, phoPQ, and pmrAB). We conducted phylogenetic analyses of key K. pneumoniae multi-locus sequence types (ST258, ST17, ST307, and ST392). RESULTS: Polymyxin exposure was documented in 53/88 (60%) patients prior to PR detection. Through an analysis of key PR genes, we detected 129 individual variants and 72 unique variant combinations in PR isolates. This included multiple, distinct changes in 36% of patients with serial PR isolates. Insertion sequence disruption was limited to mgrB (P < .001). Polymyxin minimum inhibitory concentrations showed stepwise increases with the number of PR genes affected (P < .001). When clusters containing PR isolates in ≥2 patients were analyzed, 10/14 had multiple genetic events leading to PR. CONCLUSIONS: Molecular mechanisms leading to PR in clinical K. pneumoniae isolates are remarkably heterogenous, even within clusters or individual patients. Polymyxin exposure with de novo PR emergence led to PR in the majority of patients, rather than transmission. Optimizing polymyxin use should be a key strategy in stopping the spread of PR.
Authors: V Weterings; K Zhou; J W Rossen; D van Stenis; E Thewessen; J Kluytmans; J Veenemans Journal: Eur J Clin Microbiol Infect Dis Date: 2015-06-12 Impact factor: 3.267
Authors: Cesira Giordano; Simona Barnini; Constantinos Tsioutis; Monika A Chlebowicz; Effie V Scoulica; Achilleas Gikas; John W Rossen; Alexander W Friedrich; Erik Bathoorn Journal: Int J Antimicrob Agents Date: 2017-10-27 Impact factor: 5.283
Authors: Stefan E Richter; Loren Miller; Daniel Z Uslan; Douglas Bell; Karol Watson; Romney Humphries; James A McKinnell Journal: J Clin Microbiol Date: 2018-08-27 Impact factor: 11.677
Authors: Miranda E Pitt; Alysha G Elliott; Minh Duc Cao; Devika Ganesamoorthy; Ilias Karaiskos; Helen Giamarellou; Cely S Abboud; Mark A T Blaskovich; Matthew A Cooper; Lachlan J M Coin Journal: Microb Genom Date: 2018-02-12
Authors: Suely Carlos Ferreira Sampaio; Rozane de Lima Bigelli Carvalho; Marcelo Jenné Mimica; Cely Barreto da Silva; Lycia Mara Jenné Mimica; Aline Valerio de Lima; Keila de Oliveira Lima; Darlan Augusto da Costa Rocha; Jorge Luiz Mello Sampaio Journal: Braz J Microbiol Date: 2021-08-30 Impact factor: 2.214
Authors: Tania Wong Fok Lung; Daniel Charytonowicz; Kristin G Beaumont; Shivang S Shah; Shwetha H Sridhar; Claire L Gorrie; Andre Mu; Casey E Hofstaedter; David Varisco; Thomas H McConville; Marija Drikic; Brandon Fowler; Andreacarola Urso; Wei Shi; Dario Fucich; Medini K Annavajhala; Ibrahim N Khan; Irina Oussenko; Nancy Francoeur; Melissa L Smith; Brent R Stockwell; Ian A Lewis; Abderrahman Hachani; Swikrity Upadhyay Baskota; Anne-Catrin Uhlemann; Danielle Ahn; Robert K Ernst; Benjamin P Howden; Robert Sebra; Alice Prince Journal: Cell Metab Date: 2022-04-11 Impact factor: 31.373
Authors: Andrew S Bray; Richard D Smith; Andrew W Hudson; Giovanna E Hernandez; Taylor M Young; Hannah E George; Robert K Ernst; M Ammar Zafar Journal: mBio Date: 2022-03-21 Impact factor: 7.786
Authors: John P Mills; Laura J Rojas; Steve H Marshall; Susan D Rudin; Andrea M Hujer; Luke Nayak; Michael A Bachman; Robert A Bonomo; Keith S Kaye Journal: Open Forum Infect Dis Date: 2021-04-21 Impact factor: 3.835
Authors: András Fodor; Birhan Addisie Abate; Péter Deák; László Fodor; Ervin Gyenge; Michael G Klein; Zsuzsanna Koncz; Josephat Muvevi; László Ötvös; Gyöngyi Székely; Dávid Vozik; László Makrai Journal: Pathogens Date: 2020-06-29
Authors: Caroline Boulouis; Wan Rong Sia; Muhammad Yaaseen Gulam; Jocelyn Qi Min Teo; Yi Tian Png; Thanh Kha Phan; Jeffrey Y W Mak; David P Fairlie; Ivan K H Poon; Tse Hsien Koh; Peter Bergman; Chwee Ming Lim; Lin-Fa Wang; Andrea Lay Hoon Kwa; Johan K Sandberg; Edwin Leeansyah Journal: PLoS Biol Date: 2020-06-08 Impact factor: 8.029